Related Experiment Video
Updated: Jun 24, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Transforming growth factor-beta1 impairs neuropathic pain through pleiotropic effects
Stefania Echeverry1, Xiang Qun Shi, Alexandra Haw
1The Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec, Canada. Stefania.Echeverry@mail.mcgill.ca
Molecular Pain
|March 31, 2009
Summary
Transforming Growth Factor-beta1 (TGF-beta1) effectively treats neuropathic pain by reducing inflammation and protecting nerve cells. This cytokine therapy alleviates existing pain and prevents its development after nerve injury.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Neuropathic pain mechanisms following peripheral nervous system damage are complex.
- Homeostatic disturbances extend from injury sites to the spinal cord and brain.
- Neuroimmune interactions play a critical role in chronic pain development and maintenance.
Purpose of the Study:
- To investigate the efficacy of Transforming Growth Factor-beta1 (TGF-beta1) in mitigating nerve injury-induced neuropathic pain.
- To explore the therapeutic potential of TGF-beta1 in a rat model of neuropathic pain.
Main Methods:
- Utilized a partial sciatic nerve ligation model in rats to induce neuropathic pain.
- Administered intrathecal infusion of recombinant TGF-beta1.
- Assessed pain behaviors, spinal microgliosis, astrocytic activation, neuronal markers (ATF3), and inflammatory mediators (MCP-1, cytokines).
Main Results:
- Intrathecal TGF-beta1 significantly attenuated and reversed neuropathic pain.
- TGF-beta1 inhibited spinal microgliosis, microglial and astrocytic activation.
- It demonstrated neuroprotection by preventing ATF3+ neuron induction and reducing MCP-1 expression.
- TGF-beta1 suppressed spinal inflammatory responses and cytokine expression.
Conclusions:
- TGF-beta1 is an effective therapeutic agent for neuropathic pain, targeting both neurons and glial cells.
- Multipotent agents like TGF-beta1 can restore spinal cord homeostasis and reduce pain.
- Further research into TGF-beta1-based therapies holds promise for neuropathic pain management.
Related Concept Videos
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:23Degenerative Disc Disease ll: Pathophysiology
The symptoms of degenerative disc disease arise from a combination of mechanical compression, vascular compromise, and biochemical inflammation, which together disrupt nerve function and produce pain.Mechanical CompressionDisc degeneration reduces height and elasticity, predisposing to herniation of the nucleus pulposus, a major cause of radicular pain. Herniations may be protrusion (bulging with intact annulus), extrusion (nucleus extends beyond disc but remains connected), or sequestration...